Medical Devices US

US Alzheimer's Blood Tests Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

US Alzheimer's Blood Tests Market Industry Trends and Forecast to 2034: Segmented by (Biomarker, Use, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $141.8 Mn Placeholder estimate
Estimate 2025 $174.6 Mn 37.2% of the global market
Projected 2034 $1.13 Bn 549.1% Adds $958.6 Mn over 9 forecast years
CAGR 2025–2034 23.1% Faster than 97% of 180 Medical Devices markets here
Key players 5
  • US is 37.24% of the global market.
  • In North America, the largest is US (this report) at $174.6 Mn.
  • Fastest growing: Canada at 25.2% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$958.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Alzheimer's Blood Tests Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $141.8 Mn — —
2025 (base) $174.6 Mn +$32.8 Mn —
2026 (forecast) $214.9 Mn +$40.3 Mn +23.1%
2027 (forecast) $264.5 Mn +$49.6 Mn +51.5%
2028 (forecast) $325.6 Mn +$61.1 Mn +86.5%
2029 (forecast) $400.9 Mn +$75.2 Mn +129.6%
2030 (forecast) $493.5 Mn +$92.6 Mn +182.7%
2031 (forecast) $607.5 Mn +$114.0 Mn +248%
2032 (forecast) $747.8 Mn +$140.3 Mn +328.4%
2033 (forecast) $920.5 Mn +$172.7 Mn +427.3%
2034 (forecast) $1.13 Bn +$212.6 Mn +549.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Alzheimer's Blood Tests Market Analysis at a glance
Market size, 2025$174.6 Mn placeholder estimate
Forecast, 2034$1.13 Bn placeholder estimate
Growth (CAGR), 2025–203423.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledBlood-Based Biomarkers for Alzheimer's Disease
SegmentsBiomarker, use and end user (see all)
Key playersC2N Diagnostics, Roche Diagnostics, Fujirebio, Quanterix, Quest Diagnostics (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
Active clinical trials40 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Alzheimer's Blood Tests Market Analysis Executive Summary

Alzheimer's blood tests measure proteins such as p-tau and amyloid in blood to help diagnose Alzheimer's disease without a brain scan.

Key segments of the alzheimer's Blood Tests market include biomarker (p-Tau217, Amyloid Beta 42/40 and Neurofilament Light) and use (Diagnosis, Clinical Trial Screening and Monitoring).

Bar chart: US Alzheimer's Blood Tests market size, 2024–2034, placeholder estimates. $141.8 Mn in 2024, $174.6 Mn in 2025 and $1.13 Bn in 2034, 23.1% CAGR.
US Alzheimer's Blood Tests market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Alzheimer's Blood Tests Market Dynamics

Market Growth Drivers

Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the alzheimer's Blood Tests market.

Opportunity

Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the alzheimer's Blood Tests market room to grow, especially in emerging markets.

Market Restraints

Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the alzheimer's Blood Tests market.

Competitive Landscape for Alzheimer's Blood Tests Market in the US

The alzheimer's Blood Tests market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Alzheimer's Blood Tests Market in the US

Alzheimer's Blood Tests in the US: rules, payment and research

The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2] ClinicalTrials.gov lists 40 studies on Alzheimer's Blood Tests that are recruiting, active or about to start in the US.⁠[3]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how alzheimer's Blood Tests products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in the US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Alzheimer's Blood Tests right now, from free public sources.

Clinical trials

40 active trials in the US

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Roche 2 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Eli Lilly and Company 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Alzheimer's Blood Tests in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Inside the US

Quick answers

Frequently asked questions

How big is the Alzheimer's Blood Tests market in the US?
Placeholder estimate: about $174.6 Mn in 2025, rising to about $1.13 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Alzheimer's Blood Tests market in the US growing?
Placeholder estimate: about 23.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Alzheimer's Blood Tests market report cover?
The report splits the market by biomarker (p-Tau217, Amyloid Beta 42/40, Neurofilament Light), use (Diagnosis, Clinical Trial Screening, Monitoring) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Alzheimer's Blood Tests market?
Key players include C2N Diagnostics, Roche Diagnostics, Fujirebio, Quanterix and Quest Diagnostics.
What is driving the Alzheimer's Blood Tests market?
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the alzheimer's Blood Tests market.
Who regulates Alzheimer's Blood Tests in the US?
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA). Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Alzheimer's Blood Tests are running in the US?
40 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on Alzheimer's Blood Tests?
PubMed lists 504 papers on Alzheimer's Blood Tests added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in US

See all

Related on diagnostics and lab testing and alzheimer's

See the topic